Clinical trials: Moderate Respiratory Distress

COVID-19, ARDS

Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS

• Withdrawn
• Age: 18 to 80 years
• Phase 1/2

This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…

Conditions

COVID-19, ARDS, Acute Respiratory Distress Syndrome

Trial name

NCT04452097

Testing

Human umbilical cord mesenchymal stem cells + best supportive care

Sponsor

Baylx Inc.